Key result
DVT prophylaxis reaches ~90% of at-risk patients in England and Scotland, varying widely by specialty.
Why the study?
What is the prevalence of deep vein thrombosis prophylaxis among at-risk patients in acute hospital trusts?
Observational (n=742)
Yes
What is the prevalence of deep vein thrombosis prophylaxis among at-risk patients in acute hospital trusts?
DVT prophylaxis is highly prevalent among at-risk patients in acute hospital trusts, indicating that routine prophylaxis is well established for known high-risk conditions.
Answers are grounded in this paper and cite their sources.
High DVT prophylaxis rates support established UK practices; leaves open specialty optimization and outcome studies.
OBJECTIVE: The effectiveness of activities to promote routine prophylaxis to prevent thromboembolism is difficult to assess because information about the prevalence of prophylaxis is sparse. The aim of this study was to assess the prevalence of deep vein thrombosis (DVT) prophylaxis for patients at risk in general medicine, general surgery, orthopaedics and gynaecology in Scotland and the North of England. DESIGN: Retrospective case note review of a random sample of episodes of care in a stratified random sample of directorates in Scotland and a convenience sample in England. SETTING: Twenty acute hospital directorates in Scotland and eight in the North of England. PARTICIPANTS: Case notes of patients at risk of thrombosis and discharged from the selected directorates in a 12-month period (n = 742). MAIN OUTCOME MEASURES: The proportion of patients receiving prophylaxis in each directorate. RESULTS: Overall, 469/526 (89%) of patients in Scotland and 199/216 (92%) in England received prophylaxis. The proportion varied from 71% in general medicine to 100% in orthopaedics. The frequency of use of different forms of prophylaxis varied between directorates. Approximately 60% of the patients who received prophylaxis received more than one form. CONCLUSIONS: Prophylaxis for DVT is well established for procedures and conditions that are known to increase the risk of thrombosis and for which there are no contraindications. Additional efforts to promote prophylaxis for these conditions are unlikely to be cost effective. Further research is needed to establish whether rates are equally high in other conditions, and whether the high prophylaxis rates are due to clinical effectiveness initiatives.
No takes yet. Share an insight, caveat, or question.
S Campbell (2001) conducted an observational in Patients at risk of thrombosis (n=742). DVT prophylaxis was evaluated on Proportion of patients receiving prophylaxis in each directorate. DVT prophylaxis was administered to 89% of at-risk patients in Scotland and 92% in England, with rates varying by specialty from 71% in general medicine to 100% in orthopaedics.
Synapse has enriched 10 related papers. Consider them for comparative context: